Health 2.0 Europe 2016

11 - 12 May 2016, Barcelona, Spain.
The 7th edition of Health 2.0 Europe is coming back to Barcelona for 3 full days of content that will explore European and international innovation in patient-provider communication, consumer health, data analytics and more.

Over 120 speakers and 600 attendees from around the world will reconvene to experience over 50 live product demos of innovative solutions that will shake up European health systems.

Confirmed keynotes already include:

  • Esther Dyson, Chairman, EDventure Holdings (USA)
  • Dr. Rafael Grossmann, Practicing surgeon and digital health pionneer (USA)
  • Damien Marmion, Global Head of Health, AXA (France)
  • Dr. Julio Mayol, Director of Innovation, Hospital Clinico San Carlos (Spain)
  • Pēteris Zilgalvis, Head of Unit, eHealth and Well Being – DG CONNECT, European Commission (Belgium)

Confirmed digital health champions also include:

  • Artem Andrianov, CEO, Cyntegrity (Germany)
  • Jani Ahonala, Co-founder & Chairman of the Board, Noona Healthcare, (Finland)
  • Dr. Tom Albert, Director - Health Strategy, AXA Krankenversicherung AG (Germany)
  • Jordina Arcal, Co-founder & COO, HealthApp (Spain)
  • Dr. Alexander Börve, Founder and CEO, FirstDerm.com (Sweden/USA)
  • Vas Bailey, Principal, Quid, Inc (USA)
  • Vedran Boškić, Healthcare ICT consultant, Parsek (Slovenia)
  • Joan Cornet, mHealth Director, Mobile World Capital (Spain)
  • Dustin DiTommaso, SVP, Behavior Change Design, Mad*Pow (USA)
  • Dr. Eduardo García Cruz, Urologist and Men’s Health Specialist, Barcelona Hospital Clinic (Spain)
  • Jorge Gonzalez, Managing Director, TICBioMed (Spain)
  • Jamison Feramisco, President and Co-Founder, Transfuse Solutions, Inc. (USA)
  • Tal Givoly, CEO and Co-founder, Medivizor (Israel)
  • Jorge Gonzalez Olalla, Managing Director, TICBioMed (Spain)
  • Min-Sung Sean Kim, Partner, XL Health (Germany)
  • Jörg Land, CEO, Tinnitracks (Germany)
  • Robert Milnes, CEO, Fertility Focus Limited (United Kingdom)
  • Peter Ohnemus, President & CEO, Dacadoo (Switzerland)
  • Pablo Pantaleoni, CEO, MedTep (Spain/USA)
  • Michael Seres, Founder, 11Health (United Kingdom)
  • Dr. Alexander Schachinger, CEO, EPatient RSD (Germany)
  • Mitchell Silva, Founder and CEO, Esperity (Belgium)
  • Marta Sjögren, Principal, Northzone (Sweden)
  • Pierre Socha, Investment Manager, Amadeus Capital Partners (United Kingdom)
  • Ed Stafford, Director of Informatics, Genomics England (United Kingdom)
  • Unity Stoakes, ‎Co-founder and President, StartUp Health (USA)
  • Donato Tramuto, President and CEO, Healthways and Founder, Health eVillages, (USA)
  • Salvador Vera, CEO, MYSPHERA (Spain)
  • Frank Westermann, Co-founder and CEO, mysugr (Austria)

A mix of visionary keynotes and interactive panel discussions, the 2016 edition will cover some of the following overarching themes:

  • Building blocks to a dynamic health innovation ecosystem
  • Data analytics: Structuring information for decision making
  • Solutions for hospitals and health professionals
  • Gamification and design strategies for behaviour change
  • Pharma 2.0: Going beyond the pill
  • Who will pay for Health 2.0?
  • Reimbursement - Players, trends, criteria and processes
  • The rise of consumer health interfaces
  • "SHUSH topics" and the infamous Unmentionables
  • Health 2.0 applications in emerging markets

For further information and to register, please visit:
https://goo.gl/IVCb3P

PS: Get 15% discount to attend Health 2.0 Europe 2016 using the code EHNEWS16

About Health 2.0
Health 2.0 is the premiere showcase and catalyst for the advancement of new health technologies. Through a global series of conferences, developer competitions, and leading market intelligence, Health 2.0 drives the innovation and collaboration necessary to transform health and health care. In addition to our flagship event held in the Bay Area each Fall, we host events around the world including in Europe, Latin America and India, and new for 2015 Korea and Japan.

Most Popular Now

BioMotiv and Bristol-Myers Squibb announce the lau…

BioMotiv, a mission-driven drug development accelerator associated with The Harrington Project for discovery and development, that advances breakthrough discoveries from ...

CEPI and GSK announce collaboration to strengthen …

CEPI, the Coalition for Epidemic Preparedness Innovations, and GSK announced a new collaboration aimed at helping the global effort to develop a vaccine for the 2019-nCoV...

Sandoz completes acquisition of Aspen's Japanese o…

Sandoz today announced that it has successfully completed the acquisition of the Japanese business of Aspen Global Incorporated (AGI), a wholly owned subsidiary of Aspen ...

Sanofi brain-penetrant BTK inhibitor meets primary…

The Sanofi Phase 2b study evaluating its investigational BTK (Bruton's tyrosine kinase) inhibitor (SAR442168), an oral, brain-penetrant, selective small molecule, achieve...

Roche reports very strong results in 2019

In 2019, Group sales rose 9% to CHF 61.5 billion and core EPS grew 13%, ahead of sales. The core operating profit increased 11%, reflecting the strong underlying business...

Merck donates one billionth praziquantel tablet

Merck, a leading science and technology company, today announced that it has already donated 1 billion tablets of praziquantel, the standard medication for the treatment ...

Bayer and Nuvisan create new research unit in Berl…

Bayer AG today announced that it entered into a definitive agreement to transfer a large part of its Berlin-based small molecule research unit to Nuvisan, an internationa...

Novartis announces MET inhibitor capmatinib (INC28…

Novartis announced that the US Food and Drug Administration (FDA) accepted and granted Priority Review to capmatinib’s (INC280) New Drug Application (NDA). Capmatinib is ...

WHO, China leaders discuss next steps in battle ag…

The Director-General of the World Health Organization (WHO), Dr Tedros Adhanom Ghebreyesus, met President Xi Jinping of the People's Republic of China in Beijing. They sh...

FDA approves first drug for treatment of peanut al…

Today the U.S. Food and Drug Administration approved Palforzia [Peanut (Arachis hypogaea) Allergen Powder-dnfp] to mitigate allergic reactions, including anaphylaxis, tha...

Can bilingualism protect the brain even with early…

A study by York University psychology researchers provides new evidence that bilingualism can delay symptoms of dementia. Alzheimer's disease is the most common form of d...

Poliovirus therapy shows potential as cancer vacci…

A modified form of poliovirus, pioneered at Duke Cancer Institute as a therapy for glioblastoma brain tumors, appears in laboratory studies to also have applicability for...